Biogen Idec and Sobi present new data from the Phase 3 study of their long-lasting Hemophilia factor candidate ALPROLIX™
2 July 2013 | By Biogen Idec
Biogen Idec and Sobi presented new findings...
List view / Grid view
2 July 2013 | By Biogen Idec
Biogen Idec and Sobi presented new findings...
29 May 2013 | By Biogen Idec
Biogen Idec Corporate website dedicated to World MS Day awareness...
23 May 2013 | By Biogen Idec
Biogen Idec announced that Spyros Artavanis-Tsakonas, Ph.D., has been named the company’s Chief Scientific Officer...
21 May 2013 | By Biogen Idec
EMA submission planned in the coming weeks...
16 May 2013 | By Biogen Idec
“Biogen Idec Foundation & East End House share an ongoing commitment..."
13 May 2013 | By Biogen Idec
The U.S. FDA has accepted BLA for the marketing approval of ELOCTATE™...
4 April 2013 | By Biogen Idec
Results from the DAC HYP SELECT clinical trial...
2 April 2013 | By Biogen Idec
Biogen Idec has completed its purchase of Elan Corporation’s interest in TYSABRI® (natalizumab)...
27 March 2013 | By Biogen Idec
The U.S. FDA has approved TECFIDERA™...
22 March 2013 | By GCI Health
European Commission decision anticipated in second quarter of 2013...
20 March 2013 | By Biogen Idec
“These full first-year results provide a more complete picture of PLEGRIDY..."
19 March 2013 | By Biogen Idec
Patent offers protection until 2028 and strengthens growing product patent portfolio...
12 March 2013 | By Biogen Idec
“This regulatory submission marks another significant step..."
4 March 2013 | By Biogen Idec
“We are encouraged by the FDA’s acceptance of our application..."
8 February 2013 | By Biogen Idec
Biogen Idec and Swedish Orphan Biovitrum released data...